Monte Rosa Therapeutics (GLUE) EBT Margin (2024 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly EBT Margin of 1033.74% for Q1 2026, down 108992.0% year-over-year from N/an in Q1 2025, and up 2.32% quarter-over-quarter from 1058.25% in Q4 2025.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) EBT Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' EBT Margin history runs 3 years deep, the most recent figure standing at 1033.74% for Q1 2026.
- In Q1 2026, EBT Margin fell 108992.0% year-over-year to 1033.74%; the TTM figure through Mar 2026 stood at 2679.88% (down 268582.0% YoY), while the FY2025 annual figure was 18.66%, up 7408.0% from the prior year.
- EBT Margin for Q1 2026 stood at 1033.74%, up from 1058.25% in the prior quarter.
- The five-year high for EBT Margin was 56.17% in Q1 2025, with the low at 2996.71% in Q1 2024.
- The 3-year median for EBT Margin is 258.12% (2024), against an average of 659.25%.
- The sharpest annual moves came in 2025 and 2026: EBT Margin surged 305288 bps in 2025, then sank 108992 bps in 2026.
- Monte Rosa Therapeutics' EBT Margin stood at 25.72% in 2024, then plunged by 4214 bps to 1058.25% in 2025, then grew by 2 bps to 1033.74% in 2026.
- Business Quant data shows GLUE's EBT Margin at 1033.74% in Q1 2026, 1058.25% in Q4 2025, and 20.17% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - | -481.59% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -481.59% |
| Mar 31, 2026 | -1,055.84% |
| Dec 31, 2025 | -1,656.81% |
| Sep 30, 2025 | -236.98% |
| Jun 30, 2025 | -7.91% |
| Mar 31, 2025 | 56.17% |
| Dec 31, 2024 | 25.72% |
| Sep 30, 2024 | -258.12% |
| Jun 30, 2024 | -640.21% |
| Mar 31, 2024 | -2,996.71% |